High-dose contrast-enhanced MRI in multiple sclerosis

T. Koudriavtseva, C. Pozzilli, C. Di Biasi, M. Iannilli, G. Trasimeni, C. Gasperini, C. Argentino, G. F. Gualdi

Research output: Contribution to journalArticlepeer-review


Contrast-enhanced MRI is effective for assessing disease activity in multiple sclerosis (MS) and may provide an outcome measure for testing the efficacy of treatment in clinical trials. To compare the sensitivity of high-dose gadolinium-HP-DO3A with that of a standard dose of gadolinium-DTPA, we studied 16 patients with relapsing-remitting MS in the acute phase of the disease. Each underwent two MRI examinations within at most 48 h. The initial MRI study was with a standard dose of gadolinium-DTPA (0.1 mmol/kg), and the second one an experimental dose of gadolinium-HP-DO3A (0.3 mmol/kg). No adverse effects were attributed to the contrast media. The high-dose study revealed more enhancing lesions than the standard-dose study (56 vs 38). This difference was found to be more relevant for infratentorial and small lesions. Furthermore, with the higher dose, there was a marked qualitative improvement in the visibility and delineation of the lesions.

Original languageEnglish
Issue numberSUPPL. 1
Publication statusPublished - May 1996


  • Gadolinium-HP-DO3A
  • High-dose contrast-enhanced magnetic resonance imaging Gadolinium-DTPA
  • Multiple sclerosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology
  • Radiological and Ultrasound Technology


Dive into the research topics of 'High-dose contrast-enhanced MRI in multiple sclerosis'. Together they form a unique fingerprint.

Cite this